Treatment patterns and outcomes in elderly patients with ovarian cancer: a real-world data analysis

Background Advanced ovarian cancer affects predominantly older patients, who often present with increased frailty and comorbidities. Older patients with ovarian cancer are underrepresented in clinical trials, and real-world data regarding treatment tolerance and survival in the oldest age groups remain limited. We evaluated surgical approach, chemotherapy completion, and overall survival in patients aged 70 years and older, stratified into 70–79 and ≥80 years, and compared outcomes with those of patients younger than 70 years. Particular attention was given to patients aged ≥80 years, for whom data are especially scarce. Methods A retrospective cohort study included 485 patients with advanced ovarian cancer referred to Skåne University Hospital, Lund, Sweden, between January 2018 and December 2023. Patients were stratified into three age groups: <70 years, 70–79 years, and ≥80 years. Baseline characteristics were compared using descriptive statistics. Survival probabilities at 12, 24 and 36 months were estimated using Kaplan–Meier analysis, and Restricted Mean Survival Time was calculated for the same intervals. Results Radical surgery was performed in 72.6% of patients <70 years, 61.4% of those aged 70–79 years, and 43.5% of patients ≥80 years (p=0.026). Completion of standard six chemotherapy cycles decreased with age: 95.0% in patients <70 years, 89.7% in the 70–79 group, and 73.9% among those ≥80 years (p=0.001). Patients <70 years undergoing primary debulking surgery had the highest 36‑month survival (74.0%). In patients ≥80 years, corresponding 36‑month survival was 42.5%. Conclusion Older patients with advanced ovarian cancer were less likely to undergo cytoreductive surgery and less likely to complete planned chemotherapy. Although survival was generally longer among patients receiving surgical treatment, performance status rather than chronological age emerged as the most consistent independent prognostic factor. These findings support an individualized treatment approach based on functional status, disease characteristics, and treatment feasibility rather than age alone.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1977324
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment patterns and outcomes in elderly patients with ovarian cancer: a real-world data analysis

Sara Alson, Karina Liuba, Anna Norbeck, Mihaela Asp
Frontiers in Oncology
Ovarian cancer diagnosis and treatment
article

Treatment patterns and outcomes in elderly patients with ovarian cancer: a real-world data analysis

Sara Alson, Karina Liuba, Anna Norbeck, Mihaela Asp
article en

Abstract

Background Advanced ovarian cancer affects predominantly older patients, who often present with increased frailty and comorbidities. Older patients with ovarian cancer are underrepresented in clinical trials, and real-world data regarding treatment tolerance and survival in the oldest age groups remain limited. We evaluated surgical approach, chemotherapy completion, and overall survival in patients aged 70 years and older, stratified into 70–79 and ≥80 years, and compared outcomes with those of patients younger than 70 years. Particular attention was given to patients aged ≥80 years, for whom data are especially scarce. Methods A retrospective cohort study included 485 patients with advanced ovarian cancer referred to Skåne University Hospital, Lund, Sweden, between January 2018 and December 2023. Patients were stratified into three age groups: <70 years, 70–79 years, and ≥80 years. Baseline characteristics were compared using descriptive statistics. Survival probabilities at 12, 24 and 36 months were estimated using Kaplan–Meier analysis, and Restricted Mean Survival Time was calculated for the same intervals. Results Radical surgery was performed in 72.6% of patients <70 years, 61.4% of those aged 70–79 years, and 43.5% of patients ≥80 years (p=0.026). Completion of standard six chemotherapy cycles decreased with age: 95.0% in patients <70 years, 89.7% in the 70–79 group, and 73.9% among those ≥80 years (p=0.001). Patients <70 years undergoing primary debulking surgery had the highest 36‑month survival (74.0%). In patients ≥80 years, corresponding 36‑month survival was 42.5%. Conclusion Older patients with advanced ovarian cancer were less likely to undergo cytoreductive surgery and less likely to complete planned chemotherapy. Although survival was generally longer among patients receiving surgical treatment, performance status rather than chronological age emerged as the most consistent independent prognostic factor. These findings support an individualized treatment approach based on functional status, disease characteristics, and treatment feasibility rather than age alone.

Frontiers in OncologyVol. 16
Lund University (SE), Skåne University Hospital (SE)
Lunds Universitet
Good health and well-being
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon